Clinical and instrumental characteristics of patients with chronic heart failure and reduced left ventricular ejection fraction depending on the presence of type II diabetes mellitus

Main Article Content

N. A. Tkach
O. L. Filatova
T. I. Gavrilenko
G. Ye. Dudnik
N .G. Lipkan
L. G. Voronkov


The aim – to compare clinical and instrumental parameters in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) depending on the presence of type II diabetes mellitus.
Materials and methods. 490 case histories of patients in the period from 2011 to 2018 with CHF, 40–80 years of age (median – 64 years), II–IV NYHA functional class, LVEF ≤ 40 % were analyzed. The study group included mainly patients with coronary heart disease (CHD) in combination with hypertension – 403 (82.2 %) patients, with isolated CHD – 55 (11.2 %) and with hypertension – 32 (6.6 %) patients. Most patients (278 (56.7 %)) had a permanent form of atrial fibrillation. Among the subjects were 373 (76.1 %) men and 117 (23.9 %) women. Patients were included in the study in the phase of clinical compensation, i.e. in the euvolemic state. All patients were divided into two groups: group I included 338 (69 %) patients with CHF and reduced LVEF without diabetes; group II consisted of 152 (31 %) patients with CHF and reduced LVEF with type II diabetes.
Results and discussion. The analysis revealed no significant differences among patients in the study groups by age, general hemodynamic parameters, mean daily heart rate, NYHA functional class, concomitant chronic obstructive pulmonary disease and the duration of CHF. A lower percentage of patients with atrial fibrillation in group II, a higher BMI in patients in group I, Е/е´ and left ventricular myocardial mass index were higher in patients without concomitant diabetes. In the study, we obtained a significantly higher uric acid level in patients with concomitant diabetes mellitus 2 and did not receive statistical differences in oxidative stress and proinflammatory markers, NT-proBNP and insulin. There was also no significant difference in the values ​​of flow-dependent endothelial dysfunction. The combination of coronary heart disease and diabetes mellitus 2 has been shown to be a major factor of high mortality in patients with CHF. However, we did not find a difference in the life expectancy of patients with CHF and reduced LVEF with and without diabetes. We also had a significantly worse survival of patients with HbA1с above 7.4 %.
Conclusions. The 5-year survival of patients with CHF with reduced LVEF with and without diabetes mellitus 2 does not differ significantly, while among the general group of patients the worst 5-year survival was demonstrated by those with HbA1с higher than 7.4 %.

Article Details


chronic heart failure, type II diabetes mellitus, survival


Воронков Л.Г., Амосова К.М., Дзяк Г.В. та ін. Рекомендації Асоціації кардіологів України з діагностики та лікування хронічної серцевої недостатності // Серцева недостатність та коморбідні стани. – 2017.– Додаток № 1.

Воронков Л.Г. Пацієнт із ХСН в Україні: аналіз усієї популяції пацієнтів, обстежених у рамках першого національного зрізового дослідження UNIVERS // Серцева недостатність.– 2012.– № 1.– С. 8–13.

Стронгин Л.Г., Починка И.Г., Конышева М.С. Гликемиче­­ский контроль и течение хронической сердечной недостаточности у больных сахарным диабетом типа 2 // Сахарный диабет.– 2012.– № 2.– С. 17–21.

Bayliss E., Bayliss M., Ware J. еt al. Predicting declines in physical function in persons with multiple chronic medical conditions: what we can learn from the medical problem list. Health Qual // Life Outcomes.– 2004.– Vol. 37 (2).– P. 47. doi:

Damman K., Valente M., Voors A. et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis // Eur. Heart J.– 2014.– Vol. 35.– P. 455–469. doi:

Duan X., Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? //

Med. Hypotheses.– 2008.– Vol. 70 (3).– P. 578–581. doi:

Ewing D. Autonomic neuropathy and heart disease / Ed. R. Jarret.– Amsterdam: Elsevier, 1984.– P. 99–132.

Gerstein H., Swedberg K., Carlsson J. et al. CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program // Arch. Intern. Med.– 2008.– Vol. 168 (15).– P. 1699–1704. doi:

Glass C., Olefsky J. Inflammation and lipid signaling in the etiology of insulin resistance // Cell Metab.– 2012.– Vol. 15.– P. 635–645. doi: 2012.04.001.

Gustafsson I., Brendorp B., Seibaek M. et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure // J. Am. Coll. Cardiol.– 2004.– Vol. 43.– Р. 771–777. doi:

Holman R., Bethel M., Mentz R. et al. EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes // New Engl. J. Med.– 2017.– Vol. 377.– P. 1228–1239. doi:

Huxley R., Filion K., Konety S. et al. Metaanalysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation // Am. J. Cardiol.– 2011.– Vol. 108.– P. 56–62. doi:

Jialal I., Amess W., Kaur M. Management of hypertriglyceridemia in the diabetic patient // Curr. Diab. Rep.– 2010.– Vol. 10 (4).– P. 316–320. doi: 10.1007/s11892-010-0124-4.

Lee D., Austin P., Rouleau J. et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model // JAMA.– 2003.– Vol. 290 (19).– P. 2581–2587. doi:

Levelt E., Mahmod M., Piechnik S. et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes // Diabetes.– 2016.– Vol. 65.– P. 44–52. doi:–0627.

MacDonald M., Petrie M., Varyani K. et al. CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme // Eur. Heart J.– 2008.– Vol. 29.– P. 1377–1385. doi:

Nichols G., Gullion C., Koro C. et al. The incidence of congestive heart failure in type 2 diabetes: an update // Diabetes Care.– 2004.– Vol. 27.– P. 1879–1884. doi:

Pocock S., Wang D., Pfeffer M. et al. Predictor of mortality and morbidity in patients with chronic heart failure // Eur. Heart J.– 2006.– Vol. 27.– Р. 65–75. doi: 10.1093/eurheartj/ehi555.

Scirica B., Braunwald E., Raz I. et al. SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial // Circulation.– 2015.– Vol. 132.– P. 198. doi:

Seferovic P., Paulus W. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes // Eur. Heart J.– 2015.– Vol. 36.– P. 1718–1727, 1727a–1727c. doi:

Shekelle P., Rich M., Morton S. et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials // J. Am. Coll. Cardiol.– 2003.– Vol. 41.– Р. 1529–1538. doi:

Smith G., Lichtman J., Bracken M. et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis // J. Am. Coll. Cardiol.– 2006.– Vol. 47 (10).– P. 1987–1996. doi:

Solomon S., St. John Sutton M., Lamas G. et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction // Circulation.– 2002.– Vol. 106.– P. 1251. doi:

Standards of Medical Care in Diabetes–2018 Abridged for Primary Care Providers American Diabetes // Association Clinical Diabetes.– 2018.– Vol. 36 (1).– P. 14–37. doi:

Tadic M., Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice // Arch. Cardiovasc. Diseases.– 2015.– Vol. 108 (4).– P. 269–276. doi:

Targher G., Dauriz M., Laroche C. et al. ESC-HFA HF Long-Term Registry Investigators. In hospital and 1 year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry // Eur. J. Heart Fail.– 2017.– Vol. 19.– P. 54–65. doi:

Van Riet E., Hoes A., Wagenaar K. et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review // Eur. J. Heart Fail.– 2016.– Vol. 18.– P. 242–252. doi:

Vaur L., Gueret P., Lievre M. et al. DIABHYCAR Study Group. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study // Diabetes Care.– 2003.– Vol. 6.– P. 855–860. doi:

Véronique L.R. Epidemiology of heart failure // Circ. Res.– 2013.– Vol. 113 (6).– P. 646–659. doi:

Wilson P., D’Agostino R., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus // Circulation.– 2005.– Vol. 112 (20).– P. 66–72. doi:

Most read articles by the same author(s)

1 2 3 > >>